Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Non-Current Deffered Revenue (2020 - 2021)

Terns Pharmaceuticals filings provide 2 years of Non-Current Deffered Revenue readings, the most recent being $160000.0 for Q4 2021.

  • Quarterly Non-Current Deffered Revenue fell 27.27% to $160000.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $160000.0 through Dec 2021, down 27.27% year-over-year, with the annual reading at $160000.0 for FY2021, 27.27% down from the prior year.
  • Non-Current Deffered Revenue hit $160000.0 in Q4 2021 for Terns Pharmaceuticals, down from $176000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $220000.0 in Q4 2020 and bottomed at $160000.0 in Q4 2021.